What's Happening?
Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. have announced the launch of the Paradise™ Ultrasound Renal Denervation (uRDN) system in Japan, now covered by the National Health Insurance system as of March 1. This system, developed
by Recor Medical, Inc., a U.S.-based subsidiary of Otsuka Medical Devices, is designed for patients with resistant hypertension whose blood pressure remains uncontrolled despite the use of three different antihypertensive medications. The system aims to lower blood pressure by reducing the overactivity of sympathetic nerves around the renal arteries. The introduction of this treatment marks the first time ultrasound renal denervation is available in Japan, providing a new option for managing resistant hypertension.
Why It's Important?
The availability of the Paradise uRDN system in Japan is significant as it addresses the medical challenge of resistant hypertension, a condition that poses a high risk for serious complications such as cardiovascular and renal diseases. By offering a new treatment option under insurance coverage, Otsuka Medical Devices and Otsuka Pharmaceutical aim to improve patient outcomes and reduce the burden of hypertension-related health issues. This development also highlights the collaboration between medical institutions and the pharmaceutical industry to enhance healthcare solutions. The system's approval by the U.S. FDA in 2023 further underscores its potential impact on global healthcare practices.
What's Next?
Following the launch, Otsuka Medical Devices and Otsuka Pharmaceutical will co-promote the Paradise uRDN system, leveraging their expertise in cardiovascular and renal fields to ensure proper use and distribution. The Japanese Society of Hypertension, along with other medical societies, will work to ensure safe and effective treatment delivery based on established guidelines. As the system becomes more widely used, it may influence treatment protocols for resistant hypertension both in Japan and potentially in other markets where similar healthcare challenges exist.
